Sanofi's Tolebrutinib Delays Progressive MS Disability by 31%

Sep 20, 2024, 09:40 AM

Sanofi has announced that its experimental drug, tolebrutinib, has shown promising results in delaying the progression of disability in patients with non-relapsing secondary progressive multiple sclerosis. According to data from a phase 3 trial, tolebrutinib delayed the worsening of the disease by 31%. This development provides hope for patients who currently have no effective treatment options. Sanofi's data indicates a significant 31% delay in disability progression onset.